Vaccine for chikungunya virus infection
    1.
    发明授权
    Vaccine for chikungunya virus infection 有权
    基孔肯雅病毒感染疫苗

    公开(公告)号:US08865184B2

    公开(公告)日:2014-10-21

    申请号:US12439509

    申请日:2007-08-31

    Abstract: The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.

    Abstract translation: 本发明涉及能够在人和其他哺乳动物宿主中引起对基孔肯雅病毒感染的保护性免疫应答的疫苗制剂。 免疫原性制剂包含稳定制剂中纯化的灭活的基孔肯雅病毒。 讨论了病毒繁殖和纯化的方法。 灭活的病毒制剂是非传染性的,免疫原性的并且在哺乳动物宿主中引发保护性免疫应答。 免疫原性组合物被配制用于体内给予人。 本发明还讨论了使用重组病毒蛋白作为免疫的抗原开发亚单位疫苗的策略。 潜在免疫原性的重组病毒抗原可用于诊断病毒的存在。

Patent Agency Ranking